Is Biopharma’s Response To Coronavirus Off The Mark?

As biopharmas aplenty race to develop a vaccine, CureLab’s Alex Shneider says an incorrect approach risks turning the currently insignificant coronavirus threat into a deadly pandemic. He suggests that we instead focus on the development of adjuvants and immunostimulants to protect the elderly.

COVID-19: A Case For “Virtual” Biopharma?

Work-and-learn from home policies are more than employee perks. They could help thwart a pandemic. Have you adopted procedures and tools that ensure continuity when employees aren’t in the office?

The Process Behind The Potential: Therapy For HPV16-Related Malignancies

HPV-related malignancies are poised to skyrocket over the next thirty+ years. Here's a look into Cue Biopharma’s engineering-centric approach to in vivo tumor antigen specific T cell activation to treat these cancers.

Update On Advanced Rapid Microbiology Methods In Biopharma

A BioPhorum survey of biopharma end-users reveals the opportunity—and the challenge—involved in the adoption of advanced rapid microbiology methods. Audrey Chang, global head of development services at BioReliance Merck; Morven McAlister, senior director at Pall Biotech; and Scott Hooper, associate director at Merck & Co Inc. break down the data.



  • Choosing The Best Sterile Dosage Form For Your Phase 1 Needs

    When developing a parenteral product, pharmaceutical scientists are faced with a variety of choices — choices that can be conflicting or present differing advantages.

  • Adoption Of Single-Use For Final Filtration

    Moving from stainless steel to single-use assemblies for final filtration helps meet production demands and cut costs. Pre-use integrity and prototype testing and handling are important considerations.

  • Avoiding Hemolysis Blood Sample Collection Processing

    Erythrocytes have significant value in specific types of research. If your objective is biobanking these cells in an intact state then it is equally important that hemolysis and the need for a re-draw is avoided. This paper explains how hemolysis can be prevented during specimen collection and handling.

  • Shifting The Biomanufacturing Paradigm: Intensifying Upstream Processes

    Demand for mAbs creates pressure to accelerate development, improve flexibility, and reduce costs while sustaining or improving drugs.This paper explores upstream strategies to increase protein titers, which can translate into higher throughput, improved flexibility, and compressed timelines.

  • Industry Trends Changing Sterile Filtration

    To help meet the needs of both large- and small-scale operations, suppliers of sterilizing-grade filters have developed new products and technologies to help meet the needs of today’s biomanufacturing processes. Industry trends toward intensified processing and increased implementation of single-use systems are changing approaches to sterile filtration and bioburden control in biomanufacturing processes.




This e-book shares some of our experiences in the more hazardous areas, and in turn challenges you to look at your facilities and operations to apply some basic safe design philosophies to whatever you are working with, potent or not. We sincerely hope you enjoy them and continue to be safe.

More Content Collections